CION Ameerpet
Modern radiation therapy for lymphoma treats only the involved site, not large regions of the body. This guide explains involved-site radiation, radiotherapy for Hodgkin and non-Hodgkin lymphoma, and how CION delivers precise IMRT/IGRT directly.
Radiation therapy uses precisely aimed, high-energy beams to damage the DNA of lymphoma cells so they can no longer grow and divide. In lymphoma it is rarely used alone for widespread disease; instead it plays a focused, deliberate role — treating early-stage disease alongside systemic therapy, consolidating a good response, tackling a resistant or bulky site, or relieving symptoms from a pressing node. Because lymphoma cells are relatively sensitive to radiation, the doses needed are often lower than for many solid tumours.
The most important shift in recent years is where the radiation is aimed. Older techniques treated large regions of the body; today the standard is involved-site radiation therapy (ISRT) — the "radiation therapy lymphoma" approach that treats only the area the lymphoma involves, plus a small margin. This keeps disease control high while sharply cutting the dose to healthy organs, which matters because many people with lymphoma are young and live for decades after treatment.
This page explains how radiation is used in Hodgkin and non-Hodgkin lymphoma, how a course is planned and delivered, and what to expect. For the full range of options, see our Lymphoma Treatment in Hyderabad page and the Lymphoma hub. Radiation is one of several treatments — chemotherapy, immunotherapy and monoclonal antibodies, and targeted therapy — that CION delivers directly.
Modern radiation for lymphoma is far more focused than the treatments used a generation ago. International guidelines (NCCN and ESMO) now recommend involved-site radiation therapy (ISRT) as the standard field design — replacing the older wide "involved-field", "mantle" and extended-field techniques. By treating only the involved area with image-guided planning, ISRT keeps the dose to the heart, lungs, breast tissue and thyroid much lower, reducing the risk of long-term side effects while maintaining disease control. (Source: NCCN Guidelines for Hodgkin & B-cell lymphomas and ESMO Clinical Practice Guidelines.)
Radiation is chosen for specific situations, not for every lymphoma. Whether it fits your plan depends on the subtype, the stage and how the disease responded to systemic therapy.
For many early-stage lymphomas, a short course of chemotherapy (sometimes with an anti-CD20 monoclonal antibody) is followed by involved-site radiation to consolidate the response. This can allow fewer chemotherapy cycles while keeping disease control strong — a well-established approach in radiotherapy Hodgkin care.
Some very localised, slow-growing (indolent) non-Hodgkin lymphomas can be treated with radiation alone to the single involved site, with the aim of long-term control — occasionally even without any chemotherapy.
When a large ("bulky") node or a residual area remains active on PET-CT after systemic therapy, involved-site radiation can be added to consolidate the result at that specific location.
Radiation can quickly relieve symptoms from a pressing or painful node, and in the relapsed or refractory setting it can bridge a patient toward a transplant or cellular therapy coordinated at a partner facility.
CION delivers radiation therapy for lymphoma directly, using modern IMRT and IGRT planned from PET-CT-fused imaging so the involved site is defined precisely and healthy organs are protected. Just as importantly, radiation is never planned in isolation: the decision to use it, and the field, dose and timing, are set by a multidisciplinary tumour board that also manages your chemotherapy, antibody therapy and follow-up.
Alongside radiation, our team delivers chemotherapy, immunotherapy and antibody therapy, targeted therapy, molecular and PET-CT-guided assessment, watch-and-wait monitoring and survivorship care in-house. More intensive procedures — stem-cell transplant and CAR T-cell therapy — are coordinated through accredited partner facilities when they are needed. You can meet our lymphoma doctors in Hyderabad or read more about our lymphoma hospital in Hyderabad.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you've been told radiation may be needed, want to understand involved-site RT, or need a second opinion before treatment, CION's lymphoma team is here.
A course of radiation is carefully engineered before a single beam is switched on. At CION each step is delivered directly by our radiation oncology and medical physics teams.
You have a planning CT scan (a "simulation") taken in the exact position you will be treated in, often using a light immobilisation device so you lie the same way every day. Your diagnostic scans and PET-CT are then fused onto this scan, letting the radiation oncologist see precisely where the lymphoma is — or was, before chemotherapy — so the involved site can be outlined accurately.
Using the fused images, the doctor defines the involved site — the originally affected nodal or extranodal area plus a small, evidence-based margin — rather than large regions of the body. This is the core of the involved site radiation lymphoma philosophy: treat what needs treating, and spare the rest.
The physics team designs an IMRT plan that conforms the dose tightly to the target while pulling dose away from the heart, lungs, breast tissue, thyroid and salivary glands. Where a chest field is involved, techniques such as breath-hold can move the heart further from the beam. IGRT (daily image guidance) then confirms your position before every session.
Treatment is painless — you feel nothing during the beam. Each session takes only a few minutes, and the course is given as a series of small daily fractions, typically over about two to four weeks depending on the plan. Most people continue their normal routine throughout.
Because involved-site radiation treats a small, focused area, side effects are usually confined to the treated region and are milder than with the older wide-field techniques. What you might experience depends on where you are treated:
Most short-term effects settle within a few weeks of finishing. The reason modern planning works so hard to keep the treated volume and dose low is to reduce long-term risks — effects on the heart, lungs, thyroid, and a small increase in the chance of a second cancer years later. Involved-site technique, lower doses where evidence supports them, IMRT/IGRT and breath-hold all serve that goal. Managing side effects sits alongside broader supportive care — see managing lymphoma chemotherapy side effects for related guidance.
Lymphoma is among the more treatable cancers, and radiation contributes to those outcomes when used in the right setting. Published series report long-term survival for Hodgkin lymphoma of roughly 80–90% and for the common aggressive B-cell non-Hodgkin lymphoma (DLBCL) of about 60–70%, depending heavily on stage and risk factors. These are population figures — outcomes vary by individual, subtype, stage and response to treatment, so your own outlook is best discussed with your specialist. (Figures per published Hodgkin and DLBCL outcome series, consistent with NCCN and ESMO guidance.)
Radiation rarely works alone in lymphoma — it is sequenced thoughtfully with systemic therapy, and the order matters. Common patterns include:
The most common approach is a short course of chemotherapy — often with an anti-CD20 monoclonal antibody — followed by involved-site radiation to consolidate the response. Radiation may also follow immunotherapy and antibody-based treatment or targeted therapy. We describe therapies here by their drug class and mechanism; for regimen names and schedules, see the Lymphoma Treatment in Hyderabad page.
When lymphoma returns or does not respond, radiation can control a specific active site and sometimes acts as a bridge toward a stem-cell transplant or CAR T-cell therapy. Those cellular treatments are coordinated through accredited partner facilities, while CION plans and delivers the radiation and manages the wider pathway — see relapsed or refractory lymphoma.
Every plan involving radiation is discussed by CION's multidisciplinary tumour board, so the field, dose and timing are matched to your subtype, stage and response — not decided in isolation. If a clinical trial is a sensible option for your situation, that too is discussed as part of the plan.
Radiation decisions in lymphoma carry real nuance, and a second opinion is especially worthwhile in a few situations:
CION offers a dedicated, free written second-opinion service. You deserve a plan built around healing, not billing — with transparent costs explained up front. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's lymphoma tumour board — especially valuable if a large radiation field has been proposed or the sequencing with chemotherapy is unclear.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Involved-site radiation therapy is the modern, more targeted way of giving radiation for lymphoma. Instead of treating large regions of the body as older techniques did, ISRT delivers the radiation dose only to the area where the lymphoma is (or was) present, plus a small safety margin. This is planned from a CT scan taken in the treatment position, usually with the earlier PET-CT and diagnostic scans fused in. The result is a much smaller treated volume, lower dose to healthy organs such as the lungs, heart, breast tissue and thyroid, and fewer long-term side effects — while keeping the disease-control benefit. ISRT is now the standard field design recommended by NCCN and ESMO for most lymphomas that need radiation, and it is delivered directly at CION using IMRT/IGRT planning.
Both. In classical Hodgkin lymphoma, radiotherapy (radiotherapy hodgkin care) is often combined with chemotherapy for early-stage disease — a "combined-modality" approach — and involved-site radiation to the originally involved nodes is a well-established part of that. In non-Hodgkin lymphoma the picture is more varied: radiation may be used as part of first treatment for some early-stage aggressive lymphomas, as the main treatment for certain very localised low-grade lymphomas, or to consolidate a good response after chemotherapy. It is also valuable for controlling symptoms from a bulky or painful node. Whether radiation is right for a particular lymphoma depends on the subtype, stage and how it responded to systemic therapy — a decision made by CION's tumour board. See the Lymphoma Treatment in Hyderabad page for the fuller picture.
Planning begins with a CT simulation — a planning scan taken in the exact position you will be treated in, often with a light immobilisation device so you lie the same way each day. Your diagnostic scans and PET-CT are fused onto this scan so the radiation oncologist can draw the involved site precisely. A medical physics team then designs an IMRT/IGRT plan that shapes the dose tightly to the target while sparing nearby organs, and daily image guidance checks your position before each session. Treatment itself is painless and takes only a few minutes per day, given as a series of small daily fractions over roughly two to four weeks depending on the plan. CION delivers this radiation directly, in-house, alongside your systemic therapy.
Because involved-site radiation treats a small, focused area, side effects are usually confined to that region and are milder than with the older wide-field techniques. They depend on where you are treated: neck or chest radiation can cause a sore throat, mild difficulty swallowing or a dry mouth; treatment near the abdomen can cause temporary nausea; skin over the treated area may become pink or dry, like mild sunburn. Tiredness that builds over the course is common. Most short-term effects settle within a few weeks of finishing. Long-term risks — such as effects on the heart, lungs, thyroid or a small increase in the chance of a second cancer years later — are the reason modern planning works so hard to keep the treated volume and dose low. Your radiation oncologist will explain the specific risks for your site and how they are minimised.
For decades, Hodgkin and some other lymphomas were treated with large fields such as "mantle" or extended-field radiation, and with higher doses. These worked well for disease control but exposed a lot of healthy tissue, contributing to late effects such as heart disease and second cancers. The field has moved deliberately towards less toxic approaches: involved-site radiation lymphoma techniques treat only the originally involved area, doses have been lowered where evidence supports it, and IMRT/IGRT plus techniques such as breath-hold (to move the heart away from a chest field) further reduce dose to critical organs. The goal now is to keep the cure rates high while shrinking the long-term footprint of treatment — a balance CION plans carefully for every patient.
Yes, and it often is. A common approach for early-stage lymphoma is a short course of systemic therapy — chemotherapy, or chemotherapy with an anti-CD20 monoclonal antibody — followed by involved-site radiation to consolidate the response. This "combined-modality" strategy can allow fewer cycles of chemotherapy while maintaining strong disease control. Radiation may also follow immunotherapy and antibody-based treatment, or be used to treat a resistant site after other treatment. In the relapsed setting, radiation sometimes bridges a patient toward a transplant or cellular therapy that is coordinated through an accredited partner facility. The sequencing is always tailored, and at CION it is decided by a multidisciplinary tumour board rather than in isolation.
Yes. Radiation therapy — planned and delivered with modern IMRT/IGRT and involved-site technique — is one of the treatments CION provides directly, alongside chemotherapy, immunotherapy and antibody therapy, targeted therapy, molecular testing, PET-CT-guided planning, watch-and-wait monitoring and survivorship care. More intensive procedures such as stem-cell transplant and CAR T-cell therapy are coordinated through accredited partner facilities when they are needed. Every lymphoma plan that involves radiation is discussed at a tumour board so the field, dose and timing are matched to your subtype and stage. To discuss whether radiation is part of your plan, book a free consultation or explore our lymphoma hospital in Hyderabad page.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.